Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M., Chu, Xin-Jie, Bartkovitz, David +9 more·2013·Journal of Medicinal Chemistry
DOI 10.1021/jm400487c

Cited by (617)

Items 501–600 of 617

  1. The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies
    Wenxia Deng, Songyan Gao, Li Yan, Qiuju Su, Si Chen · 2026 · Pharmaceuticals
  2. The role of ubiquitin system in ageing-related diseases and potential therapeutic opportunities
    Xiaoya Ren, Xin Zhou, Zhiqiang Ma, Liu D · 2026 · Molecular Biomedicine
  3. MDM2 inhibitors in the search for an optimized neovascular age-related macular degeneration treatment
    Veronica Kon Graversen, Sai H. Chavala · 2014 · Expert Review of Ophthalmology
  4. Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability
    Yuan Tian, Brian R. Lahue, Yao Ma, Latha G. Nair, Weidong Pan, Ronald J. Doll, Timothy J. Guzi, Yao Ma, Yaolin Wang, Stephane L. Bogen · 2022 · Bioorganic & Medicinal Chemistry Letters
  5. Pharmacophore Modeling Guided by Conformational Dynamics Reveals Potent Anticancer Agents
    Nigar Kantarci-Carsibasi · 2023 · Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi
  6. Small-Molecule Inhibitors of Protein–Protein Interactions as Therapeutics
    Krishna Mohan Poluri, Khushboo Gulati, Deepak Kumar Tripathi, Nupur Nagar · 2023 · Springer eBooks
  7. Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction
    Mei Ying Hu, Chang Xu, Mingxin Xu, Siyu He, Dandan Liu · 2025 · Anti-Cancer Agents in Medicinal Chemistry
  8. Neuroblastoma and the p53 Pathway
    Lindi Chen, Deborah A. Tweddle · 2015 · Pediatric and adolescent medicine
  9. Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development
    Guoqiang Dong, Chunquan Sheng · 2018 · Springer eBooks
  10. Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti‐CD20 Antibody for the Treatment of Non‐Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
    Christian Klein, Ekkehard Mössner, Marina Bacac, Günter Fingerle‐Rowson, Pablo Umaña · 2018 · Wiley eBooks
  11. Targeting dysregulation signatures of p53-MDM2 interactions to identify newer small molecule inhibitors for cancer therapy: Insight from computational direction
    Prosper Obed Chukwuemeka, Haruna Isiyaku Umar, Opeyemi Iwaloye, Oluwaseyi Matthew Oretade, Christopher Busayo Olowosoke, Michael Omoniyi Elabiyi, Festus Omotere Igbe, Oyeyemi Janet Oretade, Joy Oseme Eigbe, Funmilayo Janet Adeojo · 2021 · Research Square
  12. Targeting the Ubiquitination Cascade for Drug Discovery
    Qi Liu, Gabriel LaPlante, Wei Zhang · 2022 · Wiley eBooks
  13. Overview of Drug Discovery Targeting PPI Systems
    Hao Ma, Jian Zhang · 2025 · Wiley eBooks
  14. Inhibition of the MDM2/p53 Interaction Design, Synthesis and Evaluation of MDM2 Inhibitors
    Mariell Pettersson · 2015 · Gothenburg University Publications Electronic Archive (Gothenburg University)
  15. Towards the Investigation of the Effects of Nitration on the Activity of the Human p53 Tumour Suppressor Protein. Nitration of the p53 Tumour Suppressor Protein
    Roslina Husaini · 2014 · Bradford Scholars (University of Bradford)
  16. Molecular Designing of Small-Molecule Inhibitors for Apoptosis Regulation
    Atsushi Yoshimori, Sei‐ichi Tanuma · 2017 · Current human cell research and applications
  17. Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction
    Yangbing Li · 2018 · Deep Blue (University of Michigan)
  18. Targeted Therapies in Mesothelioma
    Loredana Urso, Giulia Pasello · 2019 · Springer eBooks
  19. Ubiquitin and Ubiquitin-Like Proteins in Cell Cycle Regulation
    Christine A. Mills · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  20. Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia
    Tatjana Stanković · 2019 · Haematologica
  21. Cancer drugs targeting DNA replication: Molecular strategies to enhance specificity and efficacy
    Li, Yizhu · 2020
  22. An Efficient Approach Toward Drugging Undruggable Targets
    Kanae Gamo, Naomi Kitamoto, Masato T. Kanemaki, Yusuke Tominari · 2020 · Royal Society of Chemistry eBooks
  23. Discovery of AMG 232, a Small Molecule MDM2 Inhibitor in Clinical Development and its Back-up Clinical Candidate, AM-7209
    Yosup Rew, John E. Eksterowicz · 2020 · Royal Society of Chemistry eBooks
  24. Merkel Cell Polyomavirus Oncogenes Generate Targetable Synthetic Lethality
    Donglim Park · 2019 · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  25. Cancer Targets Involving the Ubiquitin Proteasome System
    Erika M. V. Araujo · 2021 · Burger's Medicinal Chemistry and Drug Discovery
  26. Risk factors influencing prognosis of patients undergoing primary retroperitoneal tumor surgery
    Lina Guo, Yun-Chao Li, Zhanfeng Sun, Hai-Yang Yan, Hui Li, Yueming Wang · 2021 · World Chinese Journal of Digestology
  27. Computational Investigation on the MDM2-Idasanutlin Interaction Using the Potential of Mean Force Method
    Pundarikaksha Das, Venkata Satish Kumar Mattaparthi · 2021 · Current Chemical Biology
  28. The tumour suppressor p53 as a supporter of DNA replication
    Ina Klusmann · 2018
  29. MDM2 as a chromatin modifier
    Sabrina Gerber · 2020
  30. Discovery of Novel Inhibitors Targeting HDM2: Virtual Screening, Molecular Dynamics Simulation, Binding affinity predication and Cell Assay
    Feng Cao, Chen Liang, Feng Xiong, Hongmei Li, Xingyong Liu, Li Zhang · 2022 · Research Square
  31. Faculty Opinions recommendation of Emerging new concepts of degrader technologies.
    Peter R Bernstein · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  32. Preparing Unnatural Amino Acids
    Nour Wasfy, Hans Renata · 2023 · Elsevier eBooks
  33. Learning Perturbation-specific Cell Representations for Prediction of Transcriptional Response across Cellular Contexts
    Gal Keinan, Karen Sayal, Alon Gonen, Jiang Zhu, Lena Granovsky, Jeremy L. England · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  34. Data from Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment
    Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp, Jinsheng Liang, Sema Kurtuluş, Gina M. Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, Roshani A. Patil et al. · 2023
  35. Data from Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach
    Brian G. Higgins, Kelli Glenn, Antje‐Christine Walz, Christian Tovar, Zoran Filipovic, Sazzad Hussain, Edmund Lee, Kenneth Daniel Kolinsky, Shahid A. Tannu, Violeta Adames et al. · 2023
  36. Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
    Lindy Vernooij, Laurel Tabe Bate-Eya, Lindy K. Alles, Jasmine Y. Lee, Bianca Koopmans, Hunter C. Jonus, Nil A. Schubert, Linda G. Schild, Daphne Lelieveld, David A. Egan et al. · 2023
  37. Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
    Lindy Vernooij, Laurel Tabe Bate-Eya, Lindy K. Alles, Jasmine Y. Lee, Bianca Koopmans, Hunter C. Jonus, Nil A. Schubert, Linda G. Schild, Daphne Lelieveld, David A. Egan et al. · 2023
  38. Research progress in small-molecule modulators of protein-protein interactions
    Bin Yang, Xiangbing Qi · 2023 · Chinese Science Bulletin (Chinese Version)
  39. Impact of p53-dependent Networks on Prognosis of chronic lymphocytic leukemia
    Esraa Adel Mahmoud Mohamed Atia, Magdy mohammed, Eman Ahmed, Nashwa Nagy El-Khazragy · 2023 · Egyptian Journal of Pure and Applied Science
  40. Preclinical Evaluation of Brigimadlin (BI 907828) As a Novel MDM2 Inhibitor in Acute Lymphoblastic Leukemia
    Erhan Aptullahoğlu · 2025 · Black Sea Journal of Engineering and Science
  41. Systematic analysis of the RGS2 degron reveals characteristics of substrate recognition by the F-box protein FBXO44
    Harrison J. McNabb, Eugene Cho, Mary Pitman, Phillip S Rushton, David L. Mobley, Benita Sjögren · 2025 · Journal of Biological Chemistry
  42. Proteasome-targeted therapies in cancer
    Vasudha Tandon, Jack Molyneux, Amy Dunne Miller, Nilabja Sikdar, Sourav Banerjee · 2025 · Elsevier eBooks
  43. Confirmation by conformation: rescue of mutant p53 in AML
    David Philip Lane · 2025 · Blood
  44. Additional file 8 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  45. Additional file 3 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  46. Additional file 5 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  47. Additional file 3 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  48. Additional file 1 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  49. Additional file 1 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Ding, Li, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  50. Additional file 4 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  51. Additional file 6 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  52. Additional file 2 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  53. Additional file 7 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  54. Additional file 7 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
    Xu, Cheng, Liu, Heng, Christopher J. Pirozzi, Chen, Lee H., Paula K. Greer, Bill H. Diplas, Zhang, Liwei, Matthew S. Waitkus, Yiping He, Hai Yan · 2021 · Figshare
  55. Additional file 4 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  56. Additional file 6 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  57. Additional file 5 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Liao, Kai et al. · 2021 · Figshare
  58. Additional file 2 of Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhang, Zhiping, Chenhong Zhao, Chen, Lei, Chen, Zhiqiang, Zhang, Jie, Liu, Yaxian, Yesen Nie, He, Yanzhi, Kai Liao et al. · 2021 · Figshare
  59. Additional file 1 of First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed, Ming Zhao, Erkan Yuca, Allen Annis, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Solimar Santiago, Vincent Guerlavais et al. · 2021 · Figshare
  60. MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
    Zainab Fatima, Lihong Chen, Mulan Yin, Yunpeng Cui, Jianfeng Cai, Jiandong Chen · 2026 · Molecular Cancer Therapeutics
  61. PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugs
    Lucía Simón-Carrasco, Soledad Raya, Elena Pietrini, Manuel Luque-Perez, Marta del Rio Oliva, Ivan Rosado, Andres Joaquin Lopez-Contreras · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  62. Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis
    Davide Treré, Lorenzo Montanaro, Massimo Derenzini, Claudio Agostinelli, Enrico Derenzini · 2026 · Oncology Reviews
  63. Protein-protein interaction inhibitors in cancer
    Ian Robert Hardcastle, Jennyfer Goujon-Ricci, William Isaac Thompson · 2026 · Elsevier eBooks
  64. Synthesis and evaluation of RG7388-based fluorinated MDM2 inhibitors for developing 18F-labeled probes for PET imaging
    Atchimnaidu Siriki, Zhengyuan Zhou, Graham Ragland, Satish K. Chitneni · 2026 · European Journal of Medicinal Chemistry
  65. Selective modulation of the Protein Kinase CK2 : discovery, syntheses and characterization of non-ATP site inhibitors of CK2
    Benoît Bestgen · 2015
  66. Optimisation de peptides agonistes du récepteur CD47 : induction d'un nouveau type de mort cellulaire programmée contre les formes réfractaires de leucémie lymphoïde chronique
    Élodie Pramil · 2019 · theses.fr (ABES)
  67. La voie de signalisation FGF/FGFR : nouvelle cible thérapeutique dans les liposarcomes
    Bérengère Dadone‐Montaudié · 2020
  68. Conception et évaluation de peptides inhibiteurs de l'interaction ribosomale hCINAP/RPS14 dans un but antitumoral
    Stéphane Duflocq · 2021
  69. Glioblastoma resistance to temozolomide : implication of α5β1 integrin and p53 signalling pathways
    Saidu Sani · 2020 · theses.fr (ABES)
  70. Analyse du rôle des protéines FAK et CD47 dans l'invasion tumorale du mélanome
    Antoine Mousson · 2020
  71. A yeast-based assay to screen protein-protein interaction modulators
    Aswani Sudevan · 2021
  72. Identification of potential allosteric inhibitors-modulators for the heterodimer CDC34-UBC protein-protein complex
    Hemchandra Deka, Heba Taha M. Abdelghani, Aditi Gangopadhyay, Atul Darasing Pawar, Pritee Chunarkar Patil, Shovonlal Bhowmick · 2026 · 3 Biotech
  73. RING finger E3 ubiquitin ligases: novel therapeutic opportunities in melanoma
    Ji-fang Zhang, Long-Tian Li, Yue-Ying Yang, Shi-chen Zhang, Chao Gao, Xu Zhu, He Xin, Xinyang Li · 2026 · Cellular & Molecular Biology Letters
  74. Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients
    Megan Metzger, Julian A. Waksal, Jayanshu Jain, Natalia Rosas, Margherita Maffioli, Grace Van Hyfte, Aaron Thomas Gerds, Vikas K Gupta, Francesco Passamonti, Abdulraheem Yacoub et al. · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
  75. Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
    Mai A. Mansour, Ghaneya Sayed Hassan, Khaled A. M. Abouzid · 2026 · Archiv der Pharmazie
  76. SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma
    Giulio Aceto, Kexin Liu, Azadeh Arabzadeh, Shuhe Tsai, Yibo Xue, Anie Monast, Virginie Pilon, Mengke Han, Geneviève Morin, Kitty Pavlakis et al. · 2026 · Nature Communications
  77. Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms
    Kian K. Hershberger, Jenna Thibodeau, Yongwei Su, Sai Samanvitha Madagundapalli Ramakrishna, Vijendra Singh, Aditi Sharma, Holly J. Edwards, Yubin Ge, Jay Yang · 2026 · Biochemical Pharmacology
  78. Ubiquitination in cardiovascular diseases: From molecular mechanisms to therapeutic targeting
    Jia-Yin Wang, Tie‐Ning Zhang, Ni Yang, Peng-Hui Hao, Yue Zheng, Ri Wen · 2026 · Ageing Research Reviews
  79. Development of chimeric molecules from isoindolinone derivatives
    Т. А. Григорьева, A. N. Sokolova, D. A. Nechepurenko, A. A. Romanova, Vyacheslav G. Tribulovich · 2026 · Russian Chemical Bulletin
  80. Hybrid AI-physics screening prioritizes candidate dual MDM2/MDM4 inhibitors from a drug-like library for dedifferentiated liposarcoma
    Solomon Sackitey, Prince Danan Biniyam, Charles Lamptey Mireku, Alberta Hammah, Jesse Ayim Buabeng, Lawrence Kwame Nkrumah, Wise Mawuli Asare, Josephine Frimpomaa Oppong, Emmanuel Gyamfi Obeng, Kwabena Adu-Adjei et al. · 2026 · Research Square
  81. The p53-Associated Regulation of ATF4 mRNA Expression Involves p21 and p130 in a Stress-Dependent Manner
    Alexandra A. Dalina, Maria Shilyaeva, Ирина Ковалева, Peter M. Chumakov · 2026 · Cells
  82. Facile synthesis of trans racemic 1,4-diaryl substituted, proline esters via Ugi multicomponent reaction
    Siva Krishna Polineni, P. Sathya Shanker, Tony Kurissery Anthappan, Vipin A. Nair · 2026 · RSC Advances
  83. Strategies for Overcoming Acquired Resistance of Tumor Cells to MDM2 Inhibitors
    Nikolay V. Pervushin, Екатерина Сергеевна Просандеева, Boris Zhivotovsky, Gelina S. Kopeina · 2026 · Biochemistry (Moscow)
  84. BindingDB Entry 50021182: Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction.
    BindingDB · 2025 · UC San Diego
  85. BindingDB Entry 50020914: Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
    BindingDB · 2025 · UC San Diego
  86. BindingDB Entry 50020579: Design and Development of IKZF2 and CK1α Dual Degraders.
    BindingDB · 2024 · UC San Diego
  87. BindingDB Entry 50007839: The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    BindingDB · 2021 · UC San Diego
  88. BindingDB Entry 50045000: Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
    BindingDB · 2016 · UC San Diego
  89. BindingDB Entry 50010808: Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
    BindingDB · 2021 · UC San Diego
  90. BindingDB Entry 50021782: Expanding the ligand spaces for E3 ligases for the design of protein degraders.
    BindingDB · 2025 · UC San Diego
  91. BindingDB Entry 7643: A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    BindingDB · 2017 · UC San Diego
  92. BindingDB Entry 50045771: Quinofuracins A-E, produced by the fungus Staphylotrichum boninense PF1444, show p53-dependent growth suppression.
    BindingDB · 2016 · UC San Diego
  93. BindingDB Entry 50045585: Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.
    BindingDB · 2016 · UC San Diego
  94. BindingDB Entry 50043777: TBA
    BindingDB · 2014 · UC San Diego
  95. BindingDB Entry 50045594: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    BindingDB · 2016 · UC San Diego
  96. BindingDB Entry 50003121: Role of p53 circuitry in tumorigenesis: A brief review.
    BindingDB · 2020 · UC San Diego
  97. BindingDB Entry 50021131: An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
    BindingDB · 2025 · UC San Diego
  98. BindingDB Entry 50003153: The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
    BindingDB · 2020 · UC San Diego
  99. BindingDB Entry 50014764: Discovery of
    BindingDB · 2023 · UC San Diego
  100. BindingDB Entry 50014421: Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.
    BindingDB · 2022 · UC San Diego